NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $31.40 -0.01 (-0.02%) As of 12:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CPRX alerts:Sign Up Key Stats Today's Range$31.39▼$31.4150-Day Range$25.34▼$31.4052-Week Range$19.05▼$32.56Volume319,946 shsAverage Volume1.75 million shsMarket Capitalization$3.84 billionP/E Ratio18.04Dividend YieldN/APrice Target$32.00Consensus RatingModerate Buy Company Overview Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations. The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS). In addition, Catalyst markets Ruzurgi® (amifampridine) tablets for pediatric LEMS patients. Beyond these approved therapies, Catalyst is advancing its pipeline programs that aim to extend its expertise in ion channel modulators to other rare and difficult-to-treat conditions. Founded in 2002 and headquartered in Coral Gables, Florida, Catalyst Pharmaceuticals went public on the Nasdaq Stock Market. The company focuses its operations on clinical development, regulatory strategy and commercialization activities within the United States. Catalyst continues to explore opportunities for international collaborations and licensing arrangements to broaden patient access to its rare disease portfolio. Catalyst is led by President and Chief Executive Officer Patrick J. McEnany, who brings extensive experience in pharmaceutical product development and commercialization. Under his leadership, the company has strengthened its regulatory and commercial capabilities while advancing its pipeline toward future regulatory filings and potential approvals.AI Generated. May Contain Errors. Read More Catalyst Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreCPRX MarketRank™: Catalyst Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 341st out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 2 strong buy ratings, 1 buy rating, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Catalyst Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageCatalyst Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth16.67% Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 16.67% in the coming year, from $2.64 to $3.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 18.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 18.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.18.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 0.95. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.47% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 3.14, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 18.49%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 7 people have searched for CPRX on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat Follows8 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPRX Stock News HeadlinesAngelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals StoryMay 20, 2026 | finance.yahoo.comCatalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better StoryMay 13, 2026 | seekingalpha.comThe Treasury just bought its own debtOn April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - while former Treasury Secretary Hank Paulson publicly warned of collapsing demand for U.S. bonds. According to Garrett Goggin, CFA, CMT, with 20 years studying gold and debt cycles, this is the moment miners priced for a world that no longer exists stand to benefit most. As natural bond buyers disappear and the Fed steps in, the move in gold may only be beginning.June 24 at 1:00 AM | Golden Portfolio (Ad)Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?May 12, 2026 | prnewswire.comCatalyst Pharmaceuticals Reports First Quarter 2026 Financial ResultsMay 11, 2026 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)May 11, 2026 | globenewswire.comCatalyst Pharmaceuticals Buyout And FIRDAPSE Patents Reframe Investor OutlookMay 10, 2026 | finance.yahoo.comCatalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRXMay 9, 2026 | businesswire.comSee More Headlines CPRX Stock Analysis - Frequently Asked Questions How have CPRX shares performed this year? Catalyst Pharmaceuticals' stock was trading at $23.34 on January 1st, 2026. Since then, CPRX shares have increased by 34.5% and is now trading at $31.3950. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its earnings results on Thursday, November, 6th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.18. The biopharmaceutical company earned $148.39 million during the quarter, compared to analysts' expectations of $136.79 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.76% and a net margin of 37.08%. Read the conference call transcript. Is Catalyst Pharmaceuticals doing a stock buyback? Catalyst Pharmaceuticals' Board of Directors initiated a share repurchase plan on Wednesday, October 1st 2025, which authorizes the company to repurchase $200,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 8.3% of its stock through open market purchases. Stock buyback plans are often a sign that the company's leadership believes its stock is undervalued. Who are Catalyst Pharmaceuticals' major shareholders? Top institutional shareholders of Catalyst Pharmaceuticals include Dimensional Fund Advisors LP (2.80%), Bank of America Corp DE (2.48%), Renaissance Technologies LLC (1.92%) and Janus Henderson Group PLC (1.63%). Insiders that own company stock include Steve Miller, David S Tierney, Brian Elsbernd, Richard J Daly, Gary Ingenito, Alicia Grande, Preethi Sundaram, Carmen Jeffrey Del and Molly Harper. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings11/06/2025Today6/24/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 CPRX's financial health is in the Green zone, according to TradeSmith. CPRX has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CPRX CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Price Target for Catalyst Pharmaceuticals$32.00 High Price Target$33.00 Low Price Target$31.50 Potential Upside/Downside+1.9%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$1.74 Trailing P/E Ratio18.04 Forward P/E Ratio11.89 P/E Growth0.95Net Income$214.33 million Net Margins37.08% Pretax Margin49.66% Return on Equity35.76% Return on Assets31.31% Debt Debt-to-Equity RatioN/A Current Ratio7.10 Quick Ratio6.84 Sales & Book Value Annual Sales$588.99 million Price / Sales6.53 Cash Flow$2.92 per share Price / Cash Flow10.74 Book Value$7.76 per share Price / Book4.05Miscellaneous Outstanding Shares122,420,000Free Float109,688,000Market Cap$3.84 billion OptionableOptionable Beta0.74 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CPRX) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredBLOODBATH: 80% Dow Drop Predicted – Former Pentagon AdvisorA former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...Paradigm Press | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredVWAV: An Under-the-Radar Defense PlayVisionWave Holdings (NASDAQ: VWAV) is developing a multi-domain defense platform combining AI-powered analytic...Equiscreen | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
